The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.
Precision oncology in metastatic colorectal cancer — from biology to medicine
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Mutations of the BRAF gene in human cancer
Davies, H., Bignell, G. R., Cox, C., Stephens, P., Edkins, S., Clegg, S., Teague, J., Woffendin, H., Garnett, M. J., Bottomley, W., et al. (2002) · Nature · doi:10.1038/nature00766 · Cited by 10,674
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035
Self-citationCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer
Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., Aranda Aguilar, E., Bardelli, A., Benson, A., Bodoky, G., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw235 · Cited by 3,421
Self-citationWild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207
Self-citationPembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer
André, T., Shiu, K.-K., Kim, T. W., Jensen, B. V., Jensen, L. H., Punt, C., Smith, D., Garcia-Carbonero, R., Benavides, M., Gibbs, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2017699 · Cited by 3,099
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
Self-citation
Research works printed but not linked: 187
- Guinney, J. et al. The consensus molecular subtypes of colorectal cancer. Nat. Med. 21, 1350–1356 (2015). · DOI · Paper page
- Remon, J. & Dienstmann, R. Precision oncology: separating the wheat from the chaff. ESMO Open 3, e000446 (2018). · DOI
- Banerji, U. & Workman, P. Critical parameters in targeted drug development: the pharmacological audit trail. Semin. Oncol. 43, 436–445 (2016). · DOI
- Yap, T. A., Sandhu, S. K., Workman, P. & de Bono, J. S. Envisioning the future of early anticancer drug development. Nat. Rev. Cancer 10, 514–523 (2010). A framework for evidence-based decision-making during drug discovery and development. · DOI · Paper page
- Corcoran, R. B. et al. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2, 227–235 (2012). The first evidence of the mechanism of resistance to BRAF inhibitor in BRAF-mutant CRC through feedback reactivation of the EGFR-MAPK axis. · DOI · Paper page
- Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740–754 (2016). · DOI · Paper page
- Najgebauer, H. et al. CELLector: genomics-guided selection of cancer in vitro models. Cell Syst. 10, 424–4326 (2020). · DOI
- Ballard, D. H., Boyer, C. J. & Alexander, J. S. Organoids – preclinical models of human disease. N. Engl. J. Med. 380, 1981–1982 (2019). · DOI
- Hidalgo, M. et al. Patient-derived xenograft models: an emerging platform for translational cancer research. Cancer Discov. 4, 998–1013 (2014). · DOI · Paper page
- Byrne, A. T. et al. Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nat. Rev. Cancer 17, 254–268 (2017). · DOI · Paper page
- Rad, R. et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 24, 15–29 (2013). · DOI · Paper page
- Bürtin, F., Mullins, C. S. & Linnebacher, M. Mouse models of colorectal cancer: past, present and future perspectives. World J. Gastroenterol. 26, 1394–1426 (2020). · DOI · Paper page
- Diaz, L. A. & Bardelli, A. Liquid biopsies: genotyping circulating tumor DNA. J. Clin. Oncol. 32, 579–586 (2014). · DOI · Paper page
- Normanno, N., Cervantes, A., Ciardiello, F., De Luca, A. & Pinto, C. The liquid biopsy in the management of colorectal cancer patients: current applications and future scenarios. Cancer Treat. Rev. 70, 1–8 (2018). · DOI
- Siravegna, G., Marsoni, S., Siena, S. & Bardelli, A. Integrating liquid biopsies into the management of cancer. Nat. Rev. Clin. Oncol. 14, 531–548 (2017). · DOI · Paper page
- Siravegna, G. et al. Plasma HER2 (ERBB2) copy number predicts response to HER2-targeted therapy in metastatic colorectal cancer. Clin. Cancer Res. 25, 3046–3053 (2019). · DOI
- Khan, K. H. et al. Longitudinal liquid biopsy and mathematical modeling of clonal evolution forecast time to treatment failure in the PROSPECT-C phase II colorectal cancer clinical trial. Cancer Discov. 8, 1270–1285 (2018). · DOI · Paper page
- Parikh, A. R. et al. Serial ctDNA monitoring to predict response to systemic therapy in metastatic gastrointestinal cancers. Clin. Cancer Res. 26, 1877–1885 (2020). · DOI
- Siravegna, G. et al. How liquid biopsies can change clinical practice in oncology. Ann. Oncol. 30, 1580–1590 (2019). · DOI · Paper page
- Ciardiello, D. et al. Immunotherapy of colorectal cancer: challenges for therapeutic efficacy. Cancer Treat. Rev. 76, 22–32 (2019). · DOI · Paper page
- Germano, G. et al. Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth. Nature 552, 116–120 (2017). · DOI · Paper page
- Rospo, G. et al. Evolving neoantigen profiles in colorectal cancers with DNA repair defects. Genome Med. 11, 42 (2019). · DOI
- Germano, G., Amirouchene-Angelozzi, N., Rospo, G. & Bardelli, A. The clinical impact of the genomic landscape of mismatch repair-deficient cancers. Cancer Discov. 8, 1518–1528 (2018). · DOI
- Olson, B., Li, Y., Lin, Y., Liu, E. T. & Patnaik, A. Mouse models for cancer immunotherapy research. Cancer Discov. 8, 1358–1365 (2018). · DOI · Paper page
- Segal, N. H. & Saltz, L. B. Translational considerations on the outlook of immunotherapy for colorectal cancer. Curr. Colorectal Cancer Rep. 11, 92–97 (2015). · DOI
- Chalabi, M. et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat. Med. 26, 566–576 (2020). · DOI · Paper page
- Wieduwilt, M. J. & Moasser, M. M. The epidermal growth factor receptor family: biology driving targeted therapeutics. Cell. Mol. Life Sci. 65, 1566 (2008). · DOI · Paper page
- Mendelsohn J, B. J. The EGF receptor family as targets for cancer therapy. Oncogene 19, 6550–6565 (2000). · DOI · Paper page
- Salomon, D. S., Brandt, R., Ciardiello, F. & Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit. Rev. Oncol. Hematol. 19, 183–232 (1995). · DOI · Paper page
- Wu, X., Fan, Z., Masui, H., Rosen, N. & Mendelsohn, J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J. Clin. Invest. 95, 1897–1905 (1995). · DOI · Paper page
- Ciardiello, F. & Tortora, G. EGFR antagonists in cancer treatment. N. Engl. J. Med. 358, 1160–1174 (2008). · DOI · Paper page
- Saltz, L. B. et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J. Clin. Oncol. 22, 1201–1208 (2004). The first trial demonstrating the clinical efficacy of an anti-EGFR agent in mCRC. · DOI · Paper page
- Mendelsohn, J. & Baselga, J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J. Clin. Oncol. 21, 2787–2799 (2003). · DOI · Paper page
- Chung, K. Y. et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J. Clin. Oncol. 23, 1803–1810 (2005). · DOI · Paper page
- Lièvre, A. et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 66, 3992–3995 (2006). · DOI · Paper page
- Karapetis, C. S. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med. 359, 1757–1765 (2008). · DOI · Paper page
- Segelov, E. et al. Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian Gastro-Intestinal Trials Group ICECREAM study. J. Clin. Oncol. 34, 2258–2264 (2016). · DOI
- Siena, S. et al. Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in KRAS-mutant metastatic colorectal cancer. PLoS ONE 8, e62264 (2013). · DOI
- Douillard, J.-Y. et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J. Clin. Oncol. 28, 4697–4705 (2010). · DOI · Paper page
- Bardelli, A. & Siena, S. Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer. J. Clin. Oncol. 28, 1254–1261 (2010). · DOI · Paper page
- Sartore-Bianchi, A. et al. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies. Cancer Res. 69, 1851–1857 (2009). · DOI · Paper page
- van Brummelen, E. M. J., de Boer, A., Beijnen, J. H. & Schellens, J. H. M. BRAF mutations as predictive biomarker for response to anti-EGFR monoclonal antibodies. Oncologist 22, 864–872 (2017). · DOI
- Rowland, A. et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br. J. Cancer 112, 1888–1894 (2015). · DOI · Paper page
- Pietrantonio, F. et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur. J. Cancer 51, 587–594 (2015). · DOI · Paper page
- Smith, C. G. et al. Somatic profiling of the epidermal growth factor receptor pathway in tumors from patients with advanced colorectal cancer treated with chemotherapy ± cetuximab. Clin. Cancer Res. 19, 4104–4113 (2013). · DOI
- Loupakis, F. et al. KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br. J. Cancer 101, 715–721 (2009). · DOI · Paper page
- Peeters, M. et al. Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin. Cancer Res. 19, 1902–1912 (2013). · DOI · Paper page
- Karapetis, C. S. et al. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer–results from NCIC CTG/AGITG CO.17. Clin. Cancer Res. 20, 744–753 (2014). · DOI · Paper page
- Orlandi, A. et al. BRAF in metastatic colorectal cancer: the future starts now. Pharmacogenomics 16, 2069–2081 (2015). · DOI
- Zhao, L. & Vogt, P. K. Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanisms. Proc. Natl Acad. Sci. USA 105, 2652–2657 (2008). · DOI · Paper page
- Day, F. L. et al. PIK3CA and PTEN gene and exon mutation-specific clinicopathologic and molecular associations in colorectal cancer. Clin. Cancer Res. 19, 3285–3296 (2013). · DOI
- Perrone, F. et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann. Oncol. 20, 84–90 (2009). · DOI · Paper page
- Huang, L. et al. Anti-epidermal growth factor receptor monoclonal antibody-based therapy for metastatic colorectal cancer: a meta-analysis of the effect of PIK3CA mutations in KRAS wild-type patients. Arch. Med. Sci. 10, 1–9 (2014). · DOI
- Sepulveda, A. R. et al. Molecular biomarkers for the evaluation of colorectal cancer: guideline from the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. J. Clin. Oncol. 35, 1453–1486 (2017). · DOI · Paper page
- Ciardiello, F. et al. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann. Oncol. 27, 1055–1061 (2016). · DOI
- Scartozzi, M. et al. Analysis of HER-3, insulin growth factor-1, nuclear factor-kB and epidermal growth factor receptor gene copy number in the prediction of clinical outcome for K-RAS wild-type colorectal cancer patients receiving irinotecan-cetuximab. Ann. Oncol. 23, 1706–1712 (2012). · DOI · Paper page
- Martinelli, E. et al. AXL is an oncotarget in human colorectal cancer. Oncotarget 6, 23281–23296 (2015). · DOI
- Cardone, C. et al. AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer. Eur. J. Cancer 138, 1–10 (2020). · DOI
- De Robertis, M. et al. Dysregulation of EGFR pathway in EphA2 cell subpopulation significantly associates with poor prognosis in colorectal cancer. Clin. Cancer Res. 23, 159–170 (2017). · DOI · Paper page
- Martini, G. et al. EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving antiepidermal growth factor receptor therapy in colorectal cancer. Mol. Cancer Ther. 18, 845–855 (2019). · DOI
- Pietrantonio, F. et al. ALK, ROS1, and NTRK rearrangements in metastatic colorectal cancer. J. Natl Cancer Inst. 109, djx089 (2017). · DOI · Paper page
- Cremolini, C. et al. Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. Ann. Oncol. 28, 3009–3014 (2017). · DOI
- Morano, F. et al. Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy. J. Clin. Oncol. 37, 3099–3110 (2019). · DOI
- Bettegowda, C. et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl. Med. 6, 224ra24 (2014). · DOI · Paper page
- Martini, G. et al. Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: what does still need to be addressed? Cancer Treat. Rev. 86, 102023 (2020). · DOI
- Russo, M. et al. Tumor heterogeneity and lesion-specific response to targeted therapy in colorectal cancer. Cancer Discov. 6, 147–153 (2016). · DOI · Paper page
- Troiani, T. N. S., Vitagliano, D., Morgillo, F., Capasso, A., Sforza, V. et al. Primary and acquired resistance of colorectal cancer cells to anti-EGFR antibodies converge on MEK/ERK pathway activation and can be overcome by combined MEK/EGFR inhibition. Clin. Cancer Res. 20, 3775–3786 (2014). · DOI · Paper page
- Siena, S. et al. Dynamic molecular analysis and clinical correlates of tumor evolution within a phase II trial of panitumumab-based therapy in metastatic colorectal cancer. Ann. Oncol. 29, 119–126 (2018). · DOI
- Siravegna, G. et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat. Med. 21, 795–801 (2015). · DOI · Paper page
- Siravegna, G. et al. Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer. Cancer Cell 34, 148–1627 (2018). · DOI · Paper page
- Parseghian, C. M. et al. Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge. Ann. Oncol. 30, 243–249 (2019). · DOI · Paper page
- Dienstmann, R. et al. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat. Rev. Cancer 17, 79–92 (2017). · DOI · Paper page
- Garrett, T. P. J. et al. The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol. Cell 11, 495–505 (2003). · DOI · Paper page
- Siena, S. et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann. Oncol. 29, 1108–1119 (2018). · DOI · Paper page
- Valtorta, E. et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod. Pathol. 28, 1481–1491 (2015). · DOI · Paper page
- Seo, A. N. et al. HER2 status in colorectal cancer: its clinical significance and the relationship between HER2 gene amplification and expression. PLoS ONE 9, e98528 (2014). · DOI · Paper page
- Nam, S. K. et al. BRAF, PIK3CA, and HER2 oncogenic alterations according to KRAS mutation status in advanced colorectal cancers with distant metastasis. PLoS ONE 11, e0151865 (2016). · DOI
- Ingold Heppner, B. et al. HER2/neu testing in primary colorectal carcinoma. Br. J. Cancer 111, 1977–1984 (2014). · DOI · Paper page
- Missiaglia, E. et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann. Oncol. 25, 1995–2001 (2014). · DOI · Paper page
- Laurent-Puig, P. et al. ERBB2 alterations a new prognostic biomarker in stage III colon cancer from a FOLFOX based adjuvant trial (PETACC8). Ann. Oncol. 27, vi151 (2016).
- Raghav, K. P. S. et al. HER2 amplification as a negative predictive biomarker for anti-epidermal growth factor receptor antibody therapy in metastatic colorectal cancer. J. Clin. Oncol. 34, 3517 (2016). · DOI
- Schuell, B., Gruenberger, T., Scheithauer, W., Zielinski, C. & Wrba, F. HER 2/neu protein expression in colorectal cancer. BMC Cancer 6, 123 (2006). · DOI
- Sun, S.-J. et al. High HER-2 protein levels correlate with clinicopathological features in colorectal cancer. J. Cancer Res. Ther. 12, 323–333 (2020).
- Sartore-Bianchi, A. et al. HER2 positivity predicts unresponsiveness to EGFR-targeted treatment in metastatic colorectal cancer. Oncologist 24, 1395–1402 (2019). · DOI · Paper page
- Brannon, A. R. et al. Comparative sequencing analysis reveals high genomic concordance between matched primary and metastatic colorectal cancer lesions. Genome Biol. 15, 454 (2014). · doi:10.1186/s13059-014-0454-7 · Paper page
- Loree, J. M. et al. Molecular landscape of ERBB2/ERBB3 mutated colorectal cancer. J. Natl Cancer Inst. 110, 1409–1417 (2018). · DOI · Paper page
- Leto, S. M. et al. Sustained inhibition of HER3 and EGFR is necessary to induce regression of HER2-amplified gastrointestinal carcinomas. Clin. Cancer Res. 21, 5519–5531 (2015). · DOI
- Martin, V. et al. HER2 gene copy number status may influence clinical efficacy to anti-EGFR monoclonal antibodies in metastatic colorectal cancer patients. Br. J. Cancer 108, 668–675 (2013). · DOI · Paper page
- Clark, J., Niedzwiecki, D., Hollis, D. & Mayer, R. Phase II trial of 5-fluororuacil (5-FU), leucovorin (LV), oxaliplatin (Ox), and trastuzumab (T) for patients with metastatic colorectal cancer (CRC) refractory to initial therapy [abstract]. Proc. Am. Soc. Clin. Oncol. 22, 3584 (2003).
- Ramanathan, R. K. et al. Low overexpression of HER-2/neu in advanced colorectal cancer limits the usefulness of trastuzumab (Herceptin) and irinotecan as therapy. A phase II trial. Cancer Invest. 22, 858–865 (2004). · DOI
- Sartore-Bianchi, A. et al. Central nervous system as possible site of relapse in ERBB2-positive metastatic colorectal cancer: long-term results of treatment with trastuzumab and lapatinib. JAMA Oncol. 6, 927–929 (2020). · DOI
- Tosi, F. et al. Long-term clinical outcome of trastuzumab and lapatinib for HER2-positive metastatic colorectal cancer. Clin. Colorectal Cancer 19, 256–262.e2 (2020). Three papers reporting the results of the HERACLES-A trial, investigating the combination of trastuzumab and lapatinib in HER2+ mCRC. · DOI · Paper page
- Sartore-Bianchi, A. et al. Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. ESMO Open 5, e000911 (2020). · DOI · Paper page
- Sakai, K. et al. Pertuzumab, a novel HER dimerization inhibitor, inhibits the growth of human lung cancer cells mediated by the HER3 signaling pathway. Cancer Sci. 98, 1498–1503 (2007). · DOI
- Lewis Phillips, G. D. et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 68, 9280–9290 (2008). · DOI · Paper page
- Ogitani, Y. et al. DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1. Clin. Cancer Res. 22, 5097–5108 (2016). · DOI · Paper page
- Siena, S. et al. Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial. Lancet Oncol. (in the press).
- Nakamura, Y. et al. TRIUMPH: Primary efficacy of a phase II trial of trastuzumab (T) and pertuzumab (P) in patients (pts) with metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) in tumour tissue or circulating tumour DNA (ctDNA): A GOZILA sub-study [abstract 526PD]. Ann. Oncol. 30 (Suppl. 5), v199–v200 (2019). · doi:10.1093/annonc/mdz246.004
- Strickler, J. H. et al. Trastuzumab and tucatinib for the treatment of HER2 amplified metastatic colorectal cancer (mCRC): initial results from the MOUNTAINEER trial [abstract 527PD]. Ann. Oncol. 30 (Suppl. 5), v200 (2019). · DOI
- Xu, J. et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: the TERRA study. J. Clin. Oncol. 36, 350–358 (2018). · DOI · Paper page
- Tol, J., Nagtegaal, I. D. & Punt, C. J. BRAF mutation in metastatic colorectal cancer. N. Engl. J. Med. 361, 98–99 (2009). · DOI · Paper page
- Roth, A. D. et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J. Clin. Oncol. 28, 466–474 (2010). · DOI · Paper page
- Giannakis, M. et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep. 15, 857–865 (2016). · DOI · Paper page
- Clarke, C. N. & Kopetz, E. S. BRAF mutant colorectal cancer as a distinct subset of colorectal cancer: clinical characteristics, clinical behavior, and response to targeted therapies. J. Gastrointest. Oncol. 6, 660–667 (2015).
- Michaloglou, C., Vredeveld, L. C., Mooi, W. J. & Peeper, D. S. BRAF(E600) in benign and malignant human tumours. Oncogene 27, 877–895 (2008). · DOI · Paper page
- Sebolt-Leopold, J. S. & Herrera, R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4, 937–947 (2004). · DOI · Paper page
- Maughan, T. S. et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 377, 2103–2114 (2011). · DOI · Paper page
- Samowitz, W. S. et al. Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res. 65, 6063–6069 (2005). · DOI · Paper page
- Tran, B. et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117, 4623–4632 (2011). · DOI · Paper page
- Ogino, S. et al. Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803. Clin. Cancer Res. 18, 890–900 (2012). · DOI · Paper page
- Taieb, J. et al. Prognostic value of BRAF and KRAS mutations in MSI and MSS stage III colon cancer. J. Natl Cancer Inst. 109, djw272 (2017). · DOI · Paper page
- Matos, I., Elez, E., Capdevila, J. & Tabernero, J. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer. Expert Opin. Emerg. Drugs 21, 267–282 (2016). · DOI
- Sinicrope, F. A. et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes. Gastroenterology 148, 88–99 (2015). · DOI · Paper page
- French, A. J. et al. Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer. Clin. Cancer Res. 14, 3408–3415 (2008). · DOI · Paper page
- Lochhead, P. et al. Microsatellite instability and BRAF mutation testing in colorectal cancer prognostication. J. Natl Cancer Inst. 105, 1151–1156 (2013). · DOI · Paper page
- Jones, J. C. et al. Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer. J. Clin. Oncol. 35, 2624–2630 (2017). · DOI · Paper page
- Cremolini, C. et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann. Oncol. 26, 2092–2097 (2015). · DOI
- Flaherty, K. T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010). · DOI · Paper page
- Long, G. V. et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N. Engl. J. Med. 371, 1877–1888 (2014). · DOI · Paper page
- Gomez-Roca, C. A. et al. Encorafenib (Lgx818), an oral Braf inhibitor, in patients (pts) with Braf V600e metastatic colorectal cancer (Mcrc): results of dose expansion in an open-label, phase 1 study [abstract 535P]. Ann. Oncol. 25 (Suppl. 4), iv182 (2014). · DOI
- Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010). · DOI · Paper page
- Corcoran, R. B. et al. Efficacy and circulating tumor DNA (ctDNA) analysis of the BRAF inhibitor dabrafenib (D), MEK inhibitor trametinib (T), and anti-EGFR antibody panitumumab (P) in patients (pts) with BRAF V600E-mutated (BRAFm) metastatic colorectal cancer (mCRC) [abstract 455O]. Ann. Oncol. 27 (Suppl. 6), vi150 (2016). · DOI
- Bendell, J. C. et al. Efficacy and tolerability in an open-label phase I/II study of MEK inhibitor trametinib (T), BRAF inhibitor dabrafenib (D), and anti-EGFR antibody panitumumab (P) in combination in patients (pts) with BRAF V600E mutated colorectal cancer (CRC) [abstract]. J. Clin. Oncol. 32 (Suppl. 15), 3515 (2014). · DOI
- Corcoran, R. B. et al. Combined BRAF and MEK inhibition with dabrafenib and trametinib in BRAF V600-mutant colorectal cancer. J. Clin. Oncol. 33, 4023–4031 (2015). · DOI · Paper page
- Corcoran, R. B. et al. BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci. Signal. 3, ra84 (2010). · DOI · Paper page
- Kopetz, S. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N. Engl. J. Med. 381, 1632–1643 (2019). Results from the BEACON-CRC phase III trial that led to the registration of cetuximab + encorafenib ± binimetinib in BRAF-mutant mCRC. · DOI · Paper page
- Grothey, A. et al. ANCHOR CRC: a single-arm, phase 2 study of encorafenib, binimetinib plus cetuximab in previously untreated BRAF V600E-mutant metastatic colorectal cancer [abstract LBA-5]. Ann. Oncol. 31 (Suppl. 3), S242–S243 (2020). · DOI
- Hong, D. S. et al. Phase IB study of vemurafenib in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with BRAFV600E mutation. Cancer Discov. 6, 1352–1365 (2016). · DOI · Paper page
- Ahronian, L. G. et al. Clinical acquired resistance to RAF inhibitor combinations in BRAF-mutant colorectal cancer through MAPK pathway alterations. Cancer Discov. 5, 358–367 (2015). · DOI · Paper page
- Oddo, D. et al. Emergence of MET hyper-amplification at progression to MET and BRAF inhibition in colorectal cancer. Br. J. Cancer 117, 347–352 (2017). · DOI
- Tie, J. et al. Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation. Int. J. Cancer 128, 2075–2084 (2011). · DOI · Paper page
- Fransen, K. et al. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. Carcinogenesis 25, 527–533 (2004). · DOI · Paper page
- Heidorn, S. J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209–221 (2010). · DOI · Paper page
- Lavoie, H. et al. Inhibitors that stabilize a closed RAF kinase domain conformation induce dimerization. Nat. Chem. Biol. 9, 428–436 (2013). · DOI · Paper page
- Schram, A. M., Chang, M. T., Jonsson, P. & Drilon, A. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat. Rev. Clin. Oncol. 14, 735–748 (2017). · DOI · Paper page
- Pulciani, S. et al. Oncogenes in solid human tumours. Nature 300, 539–542 (1982). · DOI · Paper page
- Créancier, L. et al. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma. Cancer Lett. 365, 107–111 (2015). · DOI
- Hechtman, J. F. et al. Identification of targetable kinase alterations in patients with colorectal carcinoma that are preferentially associated with wild-type RAS/RAF. Mol. Cancer Res. 14, 296–301 (2016). · DOI
- Ardini, E. et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol. Oncol. 8, 1495–1507 (2014). The first report of the sensitivity of NTRK fusion-positive CRC to TRKA inhibition. · DOI
- Vaishnavi, A., Le, A. T. & Doebele, R. C. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov. 5, 25–34 (2015). · DOI · Paper page
- Drilon, A. et al. Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 7, 400–409 (2017). · DOI · Paper page
- Nathenson, M. et al. Activity of larotrectinib in patients with TRK fusion GI malignancies [abstract O-020]. Ann. Oncol. 29 (Suppl. 5), v107 (2018). · doi:10.1093/annonc/mdy149.019
- Doebele, R.C. et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 21, 271–282 (2020). · DOI · Paper page
- Sgambato, A., Casaluce, F., Maione, P. & Gridelli, C. Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors. Expert. Rev. Anticancer. Ther. 18, 71–80 (2018). · DOI
- Amatu, A. et al. Novel CAD-ALK gene rearrangement is drugable by entrectinib in colorectal cancer. Br. J. Cancer 113, 1730–1734 (2015). · DOI
- Pietrantonio, F. et al. RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. Ann. Oncol. 29, 1394–1401 (2018). · DOI
- Weaver, A. & Bossaer, J. B. Fibroblast growth factor receptor (FGFR) inhibitors: a review of a novel therapeutic class. J. Oncol. Pharm. Pract. https://doi.org/10.1177/1078155220983425 (2020). · doi:10.1177/1078155220983425
- Pagani, F. et al. The landscape of actionable gene fusions in colorectal cancer. Int. J. Mol. Sci. 20, 5319 (2019). · DOI
- Drilon, A. et al. What hides behind the MASC: clinical response and acquired resistance to entrectinib after ETV6-NTRK3 identification in a mammary analogue secretory carcinoma (MASC). Ann. Oncol. 27, 920–926 (2016). · DOI · Paper page
- Drilon, A. et al. A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion-positive solid tumors. Cancer Discov. 7, 963–972 (2017). · DOI · Paper page
- Russo, M. et al. Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer. Cancer Discov. 6, 36–44 (2016). · DOI · Paper page
- Cocco, E., Scaltriti, M. & Drilon, A. NTRK fusion-positive cancers and TRK inhibitor therapy. Nat. Rev. Clin. Oncol. 15, 731–747 (2018). A thorough review on the key discoveries in NTRK fusion-positive cancers and their treatment. · DOI · Paper page
- Cocco, E. et al. Resistance to TRK inhibition mediated by convergent MAPK pathway activation. Nat. Med. 25, 1422–1427 (2019). The first report that MAPK reactivation through parallel signalling participates to the onset of acquired resistance to NTRK inhibitors in gastrointestinal cancers. · DOI · Paper page
- Pai, E. F. et al. Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. Nature 341, 209–214 (1989). · DOI · Paper page
- Ihle, N. T. et al. Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J. Natl. Cancer Inst. 104, 228–239 (2012). · DOI · Paper page
- Strickler, J. et al. AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: results from the CodeBreak 100 phase 1 trial [abstract SO-24]. Ann. Oncol. 31 (Suppl. 3), S226 (2020). · DOI
- Nagasaka, M. et al. KRAS G12C game of thrones, which direct KRAS inhibitor will claim the iron throne? Cancer Treat. Rev. 84, 101974 (2020). · DOI · Paper page
- Schneider, G., Schmidt-Supprian, M., Rad, R. & Saur, D. Tissue-specific tumorigenesis: context matters. Nat. Rev. Cancer 17, 239–253 (2017). · DOI · Paper page
- Li, M. & Belmonte, J. C. I. Organoids — preclinical models of human disease. N. Engl. J. Med. 380, 569–579 (2019). · DOI · Paper page
- Deming, D. A. et al. A phase I study of selumetinib (AZD6244/ARRY-142866), a MEK1/2 inhibitor, in combination with cetuximab in refractory solid tumors and KRAS mutant colorectal cancer. Invest. New Drugs 34, 168–175 (2016). · DOI · Paper page
- Neto, J. M. F. et al. Multiple low dose therapy as an effective strategy to treat EGFR inhibitor-resistant NSCLC tumours. Nat. Commun. 11, 3157 (2020). · DOI
- Ozkan-Dagliyan, I. et al. Low-dose vertical inhibition of the RAF-MEK-ERK cascade causes apoptotic death of KRAS mutant cancers. Cell Rep. 31, 107764 (2020). · DOI
- Dienstmann, R. et al. Evolving landscape of molecular prescreening strategies for oncology early clinical trials. JCO Precis. Oncol. 4, 505–513 (2020). · doi:10.1200/po.19.00398
- Colomer, R. et al. When should we order a next generation sequencing test in a patient with cancer? EClinicalMedicine 25, 100487 (2020). · DOI
- Mosele, F. et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann. Oncol. 31, 1491–1505 (2020). · DOI · Paper page
- Mateo, J. et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann. Oncol. 29, 1895–1902 (2018). The ESCAT framework to rank genomic alterations on the basis of their actionability in cancer. · DOI · Paper page
- Dickson, D. et al. The master observational trial: a new class of master protocol to advance precision medicine. Cell 180, 9–14 (2020). · DOI
- Lonardi, S. et al. The PEGASUS trial: post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients [abstract]. J. Clin. Oncol. 38 (Suppl. 15), TPS4124 (2020). · DOI
- Reilly, N. M., Novara, L., Di Nicolantonio, F. & Bardelli, A. Exploiting DNA repair defects in colorectal cancer. Mol. Oncol. 13, 681–700 (2019). · DOI
- Mauri, G., Arena, S., Siena, S., Bardelli, A. & Sartore-Bianchi, A. The DNA damage response pathway as a land of therapeutic opportunities for colorectal cancer. Ann. Oncol. 31, 1135–1147 (2020). · DOI
- Bokemeyer, C. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J. Clin. Oncol. 27, 663–671 (2009). · DOI · Paper page
- Bokemeyer, C. et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur. J. Cancer 51, 1243–1252 (2015). · DOI · Paper page
- Tveit, K. M. et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J. Clin. Oncol. 30, 1755–1762 (2012). · DOI · Paper page
- Patterson, S. D. et al. Comprehensive analysis of KRAS and NRAS mutations as predictive biomarkers for single agent panitumumab (pmab) response in a randomized, phase III metastatic colorectal cancer (mCRC) study (20020408) [abstract]. J. Clin. Oncol. 31 (Suppl. 15), 3617 (2013). · DOI
- Seymour, M. T. et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 14, 749–759 (2013). · DOI · Paper page
- Peeters, M. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J. Clin. Oncol. 28, 4706–4713 (2010). · DOI · Paper page
- Peeters, M. et al. Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI alone as second-line treatment for metastatic colorectal cancer. Clin. Cancer Res. 21, 5469–5479 (2015). · DOI · Paper page
- Innocenti, F. et al. Mutational analysis of patients with colorectal cancer in CALGB/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J. Clin. Oncol. 37, 1217–1227 (2019). · DOI · Paper page
- Schwartzberg, L. S. et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J. Clin. Oncol. 32, 2240–2247 (2014). · DOI · Paper page
- Rivera, F. et al. Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma. Int. J. Colorectal Dis. 32, 1179–1190 (2017). · DOI
- Ciardiello, F. et al. Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trial. Ann. Oncol. 25, 1756–1761 (2014). · DOI · Paper page
- Kopetz, S. et al. Randomized trial of irinotecan and cetuximab with or without vemurafenib in BRAF-mutant metastatic colorectal cancer (SWOG S1406). J. Clin. Oncol. 39, 285–294 (2017). · DOI · Paper page
- Parikh, A. R. & Corcoran, R. B. Fast-TRKing drug development for rare molecular targets. Cancer Discov. 7, 934–936 (2017). · DOI
- Park, J. J. H., Hsu, G., Siden, E. G., Thorlund, K. & Mills, E. J. An overview of precision oncology basket and umbrella trials for clinicians. CA Cancer J. Clin. 70, 125–137 (2020). · DOI · Paper page
- Sidaway, P. MSI-H: a truly agnostic biomarker? Nat. Rev. Clin. Oncol. 17, 68 (2020). · DOI
- Hyman, D. et al. Phase I and expanded access experience of LOXO-195 (BAY 2731954), a selective next-generation TRK inhibitor (TRKi) [abstract]. Cancer Res. 79 (Suppl. 13), CT127 (2019). · doi:10.1158/1538-7445.am2019-ct127
- Jarow, J. P., Lurie, P., Ikenberry, S. C. & Lemery, S. Overview of FDA’s expanded access program for investigational drugs. Ther. Innov. Regul. Sci. 51, 177–179 (2017). · DOI · Paper page
Cited by
Clinical management of metastatic colorectal cancer in the era of precision medicine
Ciardiello, F., Ciardiello, D., Martini, G., Napolitano, S., Tabernero, J., & Cervantes, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21728 · Cited by 528
Self-citationSartore-Bianchi, A., Pietrantonio, F., Lonardi, S., Mussolin, B., Rua, F., Crisafulli, G., Bartolini, A., Fenocchio, E., Amatu, A., Manca, P., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-01886-0 · Cited by 268
Self-citationThe current understanding on the impact of KRAS on colorectal cancer
Meng, M., Zhong, K., Jiang, T., Liu, Z., Kwan, H. Y., & Su, T. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.111717 · Cited by 171
Yoshino, T., Di Bartolomeo, M., Raghav, K., Masuishi, T., Loupakis, F., Kawakami, H., Yamaguchi, K., Nishina, T., Wainberg, Z., Elez, E., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38032-4 · Cited by 178
Self-citationFeng, J., Hu, Z., Xia, X., Liu, X., Lian, Z., Wang, H., Wang, L., Wang, C., Zhang, X., & Pang, X. (2023) · Oncogene · doi:10.1038/s41388-023-02676-9 · Cited by 95
Metadata
- Authors
- Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A.
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2021-04-16
- Volume
- 18
- Issue
- 8
- Pages
- 506-525
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3153990830
- Cited by
- 239
- References
- 91
- FWCI
- 6.77
- Type
- journal article
- Language
- en
- Open access
- green
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Precision oncology in metastatic colorectal cancer — from biology to medicine. https://app.cochat.ai/papers/10.1038/s41571-021-00495-z
- The paper
- Di Nicolantonio, F., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J., Trusolino, L., Bernards, R., & Bardelli, A. (2021). Precision oncology in metastatic colorectal cancer — from biology to medicine. Nature Reviews Clinical Oncology. https://doi.org/10.1038/s41571-021-00495-z
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.